Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.

Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e01814-18. doi: 10.1128/AAC.01814-18. Print 2019 Apr.

2.

Pharmacodynamic modelling of β-lactam/β-lactamase inhibitor checkerboard data: illustration with aztreonam-avibactam.

Chauzy A, Buyck J, de Jonge BLM, Marchand S, Grégoire N, Couet W.

Clin Microbiol Infect. 2019 Apr;25(4):515.e1-515.e4. doi: 10.1016/j.cmi.2018.11.025. Epub 2018 Dec 10.

3.
4.

In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15.

Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF.

J Antimicrob Chemother. 2018 Oct 1;73(10):2777-2781. doi: 10.1093/jac/dky267.

PMID:
30010951
5.

In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012-15.

Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF.

J Antimicrob Chemother. 2018 Oct 1;73(10):2782-2788. doi: 10.1093/jac/dky266.

PMID:
30010894
6.

In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.

Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e02569-17. doi: 10.1128/AAC.02569-17. Print 2018 Jul.

7.

Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii.

McLeod SM, Shapiro AB, Moussa SH, Johnstone M, McLaughlin RE, de Jonge BLM, Miller AA.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01576-17. doi: 10.1128/AAC.01576-17. Print 2018 Feb.

8.

In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015.

Karlowsky JA, Kazmierczak KM, de Jonge BLM, Hackel MA, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00472-17. doi: 10.1128/AAC.00472-17. Print 2017 Sep.

9.

In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014).

Nichols WW, de Jonge BL, Kazmierczak KM, Karlowsky JA, Sahm DF.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4743-9. doi: 10.1128/AAC.00220-16. Print 2016 Aug.

10.

Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014.

Hackel M, Kazmierczak KM, Hoban DJ, Biedenbach DJ, Bouchillon SK, de Jonge BL, Stone GG.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4677-83. doi: 10.1128/AAC.02841-15. Print 2016 Aug.

11.

Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam.

Kazmierczak KM, Biedenbach DJ, Hackel M, Rabine S, de Jonge BL, Bouchillon SK, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4490-500. doi: 10.1128/AAC.00107-16. Print 2016 Aug.

12.

In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).

de Jonge BL, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3163-9. doi: 10.1128/AAC.03042-15. Print 2016 May.

13.

In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens.

Biedenbach DJ, Huband MD, Hackel M, de Jonge BL, Sahm DF, Bradford PA.

Antimicrob Agents Chemother. 2015 Oct;59(10):6053-63. doi: 10.1128/AAC.01016-15. Epub 2015 Jul 20.

14.
15.

A novel high-throughput cell-based assay aimed at identifying inhibitors of DNA metabolism in bacteria.

Fan J, de Jonge BL, MacCormack K, Sriram S, McLaughlin RE, Plant H, Preston M, Fleming PR, Albert R, Foulk M, Mills SD.

Antimicrob Agents Chemother. 2014 Dec;58(12):7264-72. doi: 10.1128/AAC.03475-14. Epub 2014 Sep 22.

16.

Pyrazolopyrimidines establish MurC as a vulnerable target in Pseudomonas aeruginosa and Escherichia coli.

Hameed P S, Manjrekar P, Chinnapattu M, Humnabadkar V, Shanbhag G, Kedari C, Mudugal NV, Ambady A, de Jonge BL, Sadler C, Paul B, Sriram S, Kaur P, Guptha S, Raichurkar A, Fleming P, Eyermann CJ, McKinney DC, Sambandamurthy VK, Panda M, Ravishankar S.

ACS Chem Biol. 2014 Oct 17;9(10):2274-82. doi: 10.1021/cb500360c. Epub 2014 Aug 5.

PMID:
25035921
17.

Discovery of inhibitors of 4'-phosphopantetheine adenylyltransferase (PPAT) to validate PPAT as a target for antibacterial therapy.

de Jonge BL, Walkup GK, Lahiri SD, Huynh H, Neckermann G, Utley L, Nash TJ, Brock J, San Martin M, Kutschke A, Johnstone M, Laganas V, Hajec L, Gu RF, Ni H, Chen B, Hutchings K, Holt E, McKinney D, Gao N, Livchak S, Thresher J.

Antimicrob Agents Chemother. 2013 Dec;57(12):6005-15. doi: 10.1128/AAC.01661-13. Epub 2013 Sep 16.

18.

Pyrazolopyrimidinediones are selective agents for Helicobacter pylori that suppress growth through inhibition of glutamate racemase (MurI).

de Jonge BL, Kutschke A, Uria-Nickelsen M, Kamp HD, Mills SD.

Antimicrob Agents Chemother. 2009 Aug;53(8):3331-6. doi: 10.1128/AAC.00226-09. Epub 2009 May 11.

19.

Exploitation of structural and regulatory diversity in glutamate racemases.

Lundqvist T, Fisher SL, Kern G, Folmer RH, Xue Y, Newton DT, Keating TA, Alm RA, de Jonge BL.

Nature. 2007 Jun 14;447(7146):817-22.

PMID:
17568739
20.

Compound efflux in Helicobacter pylori.

Kutschke A, de Jonge BL.

Antimicrob Agents Chemother. 2005 Jul;49(7):3009-10.

21.
22.

Helicobacter pylori physiology predicted from genomic comparison of two strains.

Doig P, de Jonge BL, Alm RA, Brown ED, Uria-Nickelsen M, Noonan B, Mills SD, Tummino P, Carmel G, Guild BC, Moir DT, Vovis GF, Trust TJ.

Microbiol Mol Biol Rev. 1999 Sep;63(3):675-707. Review.

25.

The Staphylococcus aureus scdA gene: a novel locus that affects cell division and morphogenesis.

Brunskill EW, de Jonge BL, Bayles KW.

Microbiology. 1997 Sep;143 ( Pt 9):2877-82.

PMID:
9308171
27.

Transcription analysis of the Staphylococcus aureus gene encoding penicillin-binding protein 4.

Domanski TL, de Jonge BL, Bayles KW.

J Bacteriol. 1997 Apr;179(8):2651-7.

28.

Peptidoglycan composition of vancomycin-resistant Enterococcus faecium.

de Jonge BL, Gage D, Handwerger S.

Microb Drug Resist. 1996 Summer;2(2):225-9.

PMID:
9158764
29.
30.

Altered peptidoglycan composition in vancomycin-resistant Enterococcus faecalis.

de Jonge BL, Handwerger S, Gage D.

Antimicrob Agents Chemother. 1996 Apr;40(4):863-9.

31.

Increased cell size and shortened peptidoglycan interpeptide bridge of NaCl-stressed Staphylococcus aureus and their reversal by glycine betaine.

Vijaranakul U, Nadakavukaren MJ, de Jonge BL, Wilkinson BJ, Jayaswal RK.

J Bacteriol. 1995 Sep;177(17):5116-21.

32.
33.

Molecular aspects of methicillin resistance in Staphylococcus aureus.

de Lencastre H, de Jonge BL, Matthews PR, Tomasz A.

J Antimicrob Chemother. 1994 Jan;33(1):7-24. Review.

PMID:
8157576
34.

Altered muropeptide composition in Staphylococcus aureus strains with an inactivated femA locus.

de Jonge BL, Sidow T, Chang YS, Labischinski H, Berger-Bachi B, Gage DA, Tomasz A.

J Bacteriol. 1993 May;175(9):2779-82.

36.
37.

Peptidoglycan composition in heterogeneous Tn551 mutants of a methicillin-resistant Staphylococcus aureus strain.

de Jonge BL, Chang YS, Gage D, Tomasz A.

J Biol Chem. 1992 Jun 5;267(16):11255-9.

38.

Suppression of autolysis and cell wall turnover in heterogeneous Tn551 mutants of a methicillin-resistant Staphylococcus aureus strain.

de Jonge BL, de Lencastre H, Tomasz A.

J Bacteriol. 1991 Feb;173(3):1105-10. Erratum in: J Bacteriol 1991 May;173(9):3034.

40.

Polar cap formation during cell division in Escherichia coli.

Nanninga N, Wientjes FB, de Jonge BL, Woldringh CL.

Res Microbiol. 1990 Jan;141(1):103-18. Review. No abstract available.

PMID:
2194244
41.

Peptidoglycan synthesis during the cell cycle of Escherichia coli: composition and mode of insertion.

de Jonge BL, Wientjes FB, Jurida I, Driehuis F, Wouters JT, Nanninga N.

J Bacteriol. 1989 Nov;171(11):5783-94.

Supplemental Content

Loading ...
Support Center